APOC3
36 programs · 36 companies
Programs
36
Companies
36
Active Trials
22
Targeting APOC3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | PBC | |
| Doxacapivasertib | Eli Lilly | Phase 3 | Alzheimer'sDravet | |
| AZN-6294 | AstraZeneca | Phase 2/3 | Endometrial CaProstate Ca | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | SCLCIgAN | |
| ALN-5628 | Alnylam | Phase 1/2 | Breast CaLN | |
| INC-1582 | Incyte | Phase 1/2 | Heart FailureOvarian Ca | |
| Talasotorasib | Exelixis | Preclinical | SCDTTR Amyloidosis | |
| Tiratapinarof | Intellia | NDA/BLA | SLEPsA | |
| Mavutuximab | Iovance | Approved | Crohn'sCF | |
| ETN-4807 | 89bio | Phase 1/2 | GAWilms | |
| PEK-IIT-646 | Peking Univ Cancer Hosp | Phase 1 | Wet AMD | |
| CGE-9788 | Cullinan Onc | Phase 3 | PsoriasisT2D | |
| Surafotisoran | Compass Ther | Phase 2 | MDDIgAN | |
| Pexaderotide | Inhibrx (Sanofi) | Phase 1/2 | WilmsObesity | |
| CAL-3191 | Calithera Bio | Phase 1/2 | UC | |
| Fixainavolisib | Windtree Therapeutics | Phase 2/3 | PsoriasisMigraine | |
| GEN-5535 | Genprobe (Hologic) | Phase 1 | AML | |
| Capibrutinib | Savara | Phase 3 | PompeHNSCC | |
| MYO-9608 | Myokardia (BMS) | NDA/BLA | Ewing Sarcoma | |
| MOM-2836 | Momenta (J&J) | Phase 1/2 | RB | |
| 996-4673 | Alphamab | Phase 1/2 | PVNMOSD | |
| Cevimavacamten | Minerva Neuro | Phase 1 | RSVWet AMD | |
| FRE-IIT-323 | Fred Hutch | Phase 2 | Asthma | |
| DUK-IIT-581 | Duke Cancer | Phase 2 | Gastric Ca | |
| Adagrainavolisib | Circassia | Phase 2 | UCCholangiocarcinoma | |
| Capiderotide | Kiadis (Sanofi) | Phase 1/2 | SchizophreniaPancreatic Ca | |
| EXA-3015 | Exact Sciences | Phase 1 | Endometrial CaAngelman | |
| Voxasertib | Destiny Pharma | Phase 2/3 | Myelofibrosis | |
| MIR-8412 | MiRXES | Phase 1/2 | OCDEndometrial Ca | |
| TAB-3211 | Tabuk Pharma | Phase 3 | PAHBCC | |
| CHA-IIT-658 | Charité Berlin | Phase 1/2 | Bladder Ca | |
| ROY-IIT-847 | Royal Marsden | Phase 1/2 | CKD | |
| Elrazanubrutinib | Dongbao Enterprise | NDA/BLA | DravetFSGS | |
| Liralucimab | Repligen | Phase 3 | TTR Amyloidosis | |
| Sotozanubrutinib | LEO Pharma | Phase 2/3 | Atopic DermPAH | |
| Adagratuximab | Zambon | Phase 2 | ALL |